GET DAILY SIGNALSEMR, HLIO, and LECO: Weighing Three Industrial Technology Stocks
Key Takeaways
- All three companies are industrial-technology names, but they occupy very different niches: EMR is a global automation and software leader, HLIO is a specialized motion-control and electronics provider, and LECO is a dominant welding and automation franchise.
- Recent market activity has favored the larger, more diversified businesses: EMR and LECO are trading near their 52-week highs on raised guidance, while HLIO has pulled back from earlier-year peaks despite solid operating momentum.
- EMR's relative performance is supported by secular demand in power, semiconductors, and software, while LECO is benefiting from resurgent industrial production and automation backlog.
- HLIO offers the fastest earnings-recovery narrative and a cleaner balance sheet, but carries higher valuation sensitivity and more cyclical, short-cycle exposure.
- Tickeron AI Verdict: Based on trend consistency, stability, and catalyst breadth, Tickeron's AI would currently favor EMR as the most compelling of the three.
Why These Names Show Up Together
Investors screening the industrial-technology space often encounter EMR (Emerson Electric), HLIO (Helios Technologies), and LECO (Lincoln Electric Holdings) in the same watchlist. Although each serves industrial end markets, their scale, business models, and growth drivers differ sharply, making a direct stock comparison useful for both long-term investors and shorter-horizon traders evaluating relative performance and market positioning. This article reviews how the three names have behaved in recent market activity, the forces shaping sentiment, and how their risk-reward profiles compare in the current environment. I also checked this using Tickeron’s AI Screener to see how the stocks compare to others in the industry.
Emerson Electric (EMR) Update
Emerson Electric (EMR) is a St. Louis-headquartered global automation leader that sells measurement and analytical instruments, industrial valves, and process-control software and systems. Following a strategic pivot toward software and systems, it now generates meaningful revenue from high-margin automation software and test-and-measurement solutions.
In recent weeks, EMR has shown consistent relative strength, trading near the upper end of its 52-week range after reporting third-quarter fiscal 2026 results that exceeded expectations. Adjusted earnings per share (EPS) rose roughly 13% year over year, and management raised its full-year sales, earnings, and free-cash-flow outlook. Underlying orders and sales both grew, supported by resilient demand in North America and Asia and by outsize growth in semiconductor and power verticals. A growing project funnel, a backlog up roughly 7%, and strong cash generation have reinforced investor confidence, even as softness in Europe and China has remained a modest headwind. From what I see, the AI Trend Prediction Engine points to steady momentum here.
Helios Technologies (HLIO) Update
Helios Technologies (HLIO) is a Sarasota, Florida-based provider of highly engineered motion-control and electronic-controls technology, operating through Hydraulics and Electronics segments. Its products serve mobile, industrial, agricultural, and recreational end markets.
HLIO's fundamentals have improved markedly in recent quarters. The company has posted consecutive periods of double-digit pro forma sales growth, expanded gross and adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) margins, and materially reduced leverage after divesting its Custom Fluidpower business. It also raised its quarterly dividend and lifted its full-year 2026 outlook. Despite this operating momentum, the shares have been more volatile than peers: after a strong run earlier in the year, the stock pulled back from its highs, with a richer valuation and short-cycle end-market exposure contributing to heightened sensitivity. Sentiment remains split, with some analysts constructive on the recovery story and others flagging valuation risk.
Lincoln Electric Holdings (LECO) Update
Lincoln Electric Holdings (LECO) is a Cleveland-based leader in welding, cutting, and brazing products, plus a growing automation business. It operates three segments—Americas Welding, International Welding, and Harris Products Group—and serves customers in more than 160 countries.
LECO has delivered some of the strongest recent momentum among the three names. Its latest quarterly results showed sales growth of roughly 15% and record adjusted EPS, driven by volume-led demand in the Americas and Asia Pacific, resurgent industrial production, and rising automation and data-center-related activity. Management raised its full-year sales outlook, pointed to a record automation backlog, and announced a double-digit dividend increase. The shares rose sharply following the report and now trade near 52-week highs. The primary counterweight is margin pressure from input-cost inflation, particularly in energy, logistics, and electronic components, which management is addressing through incremental pricing actions. One thing that stands out is how the AI Pattern Search Engine highlights LECO’s automation exposure.
Side-by-Side Assessment
The clearest contrast among the three is scale and diversification. EMR is a large-cap platform with a growing software mix and exposure to secular themes such as electrification, semiconductors, and grid modernization; its breadth supports steadier, less cyclical demand but also means its growth rate is more moderate. LECO sits in the middle, pairing a dominant welding franchise with a higher-growth automation segment tied to industrial production and reshoring; it offers strong momentum but faces margin sensitivity to commodity and component costs. HLIO is the smallest and most recovery-oriented, with faster earnings growth potential and a strengthened balance sheet, but it carries a higher beta (a measure of volatility relative to the broader market) and is more exposed to short-cycle industrial and consumer-linked demand.
On valuation sensitivity, EMR and LECO trade at relatively full multiples reflecting their recent strength, while HLIO's higher forward multiple relative to machinery peers makes it more vulnerable if growth expectations cool. Market sentiment is most uniformly positive toward EMR, constructively split on LECO, and more contested on HLIO following its pullback.
AI Assessment
Weighing trend consistency, stability, catalyst breadth, and relative positioning, Tickeron's AI would most likely favor EMR among the three. EMR combines a durable, diversified demand base, expanding software and test-and-measurement mix, a growing backlog, and secular tailwinds in power and semiconductors—attributes that support a steadier trend profile than the more cyclical HLIO or the margin-sensitive LECO. While LECO's recent volume acceleration is compelling and HLIO offers a sharper recovery angle, EMR's balance of consistent momentum and lower cyclicality gives it the strongest probability-weighted positioning in the current market environment. I’m watching this closely as conditions evolve.
Using AI Tools in My Process
When evaluating names like these, I often turn to Tickeron’s AI Daily Buy/Sell Signals to cross-check momentum across multiple timeframes. The platform aggregates signals from hundreds of AI-driven strategies, which helps surface which stocks are showing the most consistent patterns right now. It keeps my review grounded in data without replacing my own judgment on fundamentals and risk.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
EMR in upward trend: 10-day moving average broke above 50-day moving average on September 29, 2026
The 10-day moving average for EMR crossed bullishly above the 50-day moving average on September 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 71%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on EMR as a result. In 62 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.
The Moving Average Convergence Divergence (MACD) for EMR just turned positive on October 27, 2026. Looking at past instances where EMR's MACD turned positive, the stock continued to rise in 30 of 44 cases over the following month. The odds of a continued upward trend are 68%.
Following a +2.69% 3-day Advance, the price is estimated to grow further. Considering data from situations where EMR advanced for three days, in 217 of 345 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
The Aroon Indicator entered an Uptrend today. In 150 of 274 cases where EMR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 55%.
Bearish Trend Analysis
The 10-day RSI Indicator for EMR moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 42 similar instances where the indicator moved out of overbought territory. In 17 of the 42 cases, the stock moved lower in the following days. This puts the odds of a move lower at 40%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EMR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
EMR broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 14 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 18 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 74, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 30 (best 1 - 100 worst), indicating outstanding price growth. EMR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 43 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 62 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.515) is normal, around the industry mean (4.038). P/E Ratio (35.935) is within average values for comparable stocks, (37.928). Projected Growth (PEG Ratio) (1.837) is also within normal values, averaging (1.879). Dividend Yield (0.013) settles around the average of (0.030) among similar stocks. P/S Ratio (4.409) is also within normal values, averaging (186.943).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of process controls systems, valves and analytical instruments
Industry IndustrialMachinery
Advertisement